Saturday 17 October 2026 Export QNTM’s income statement to Excel — free account

Quantum Biopharma Ltd.

In the quarter to June 2026, EPS grew 85.5% and free cash flow grew 5.88%, each against the same quarter a year earlier.

2.47 0.24 −8.86%

Follow QNTM

Alert me

Market cap: $21.9M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: n/a
Altman Z: −0.26
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 21.91

Revenue 0.23

Net Income (25.30)

Free Cash Flow (8.94)

Net Debt (9.75)

Current Ratio 1.20

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.59)

P/S ratio 70.87

P/B ratio 2.70

Past 5Y EPS Growth —

This Y EPS Growth 77.44%

Next Y EPS Growth 54.62%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 78.43%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.52%

10-year low 10-year high

P/B against its own 10 years 68.08%

10-year low 10-year high

EV/Sales against its own 10 years 15.46%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	8	5	10
Receivables	7	4	0	0
Inventory	—	0	0	0
Other	—	—	2	—
	11	12	6	10

	2023	2024	2025	Q'26
Payables	4	4	4	3
ST’ Debt	—	—	—	—
Other	0	0	—	4
	5	7	6	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(32.46%)	(44.92%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	0	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(4)	(2)	(2)	0	(8)
’24	(2)	(1)	(3)	(1)	(7)
’23	(5)	(4)	(2)	(1)	(11)
’22	(5)	(9)	(8)	(6)	(28)
’21	(5)	(7)	(5)	(4)	(21)
’20	(5)	(4)	(5)	(5)	(19)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(7)	(3)	(1)	0	(11)
’24	(2)	(1)	(3)	(2)	(8)
’23	(5)	(4)	(2)	(1)	(11)
’22	(5)	(9)	(8)	(6)	(29)
’21	(6)	(7)	(5)	(4)	(21)
’20	(5)	(4)	(5)	(5)	(19)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(3.06)	(0.47)	—	—	—
’25	(3.53)	(3.23)	(1.25)	(0.71)	(8.20)
’24	(3.25)	(0.08)	(4.37)	(5.24)	(13.12)
’23	(16.88)	(9.09)	(1.95)	(2.60)	(29.87)
’22	(9.74)	(7.79)	(12.34)	(10.39)	(39.61)
’21	(24.03)	(23.38)	(9.74)	(7.39)	(65.58)
’20	(74.03)	(31.17)	(69.48)	(15.58)	(171.43)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	888.42	223.02	83.20	59.80	40.17	49.60	2.70	2.89	Analyst estimates 2026–2028 Powerpack
	High	—	—	11,431.88	4,468.23	910.00	288.60	72.15	136.50	70.85	38.25
People
People	Employees	—	—	23	17	9	10	10	8	7	7
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	0	—	—	—	—	—	—	—
	Gross margin, %	—	—	100.00	(1,331.03)	0.00	0.00	0.00	—	—	—
	EBT	0	(4)	(18)	(34)	(28)	(34)	(27)	(18)	(15)	(27)
	EBT margin, %	0.00	0.00	(25,578.54)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	0	0	(18)	(34)	(28)	(34)	(27)	(18)	(15)	(27)
	Depreciation	—	—	0	2	4	4	5	3	0	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.03)	(0.66)	(0.96)	(360.39)	(171.43)	(65.58)	(39.61)	(29.87)	(13.12)	(8.20)
	Cash flow	(0.01)	(0.03)	(0.78)	(126.15)	(103.13)	(38.55)	(47.50)	(17.78)	(6.05)	(2.51)
	Capex	0.00	0.00	(0.17)	(6.40)	0.00	(0.93)	(0.61)	0.00	(0.88)	(0.95)
	Free cash flow	(0.01)	(0.03)	(0.95)	(132.55)	(103.13)	(39.48)	(48.11)	(17.78)	(6.93)	(3.46)
	Book value	0.08	2.32	2.15	333.74	195.73	100.58	51.20	21.20	9.18	1.55
	Shares, m	5	5	18	0	0	1	1	1	1	3
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	—	—	—	—	—	—
	P/S	—	—	0.00	165.48	—	—	—	—	—	—
	P/B	—	—	0.00	1.06	—	—	—	—	—	—
	EV/Sales	—	—	0.00	139.74	—	—	—	—	—	—
	EV/FCF	—	—	0.00	(2.29)	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	0	0	(14)	(14)	(19)	(21)	(28)	(11)	(7)	(8)
	Capex	—	(8)	(3)	(1)	—	0	0	—	(1)	(3)
	Free cash flow	0	0	(17)	(14)	(19)	(21)	(29)	(11)	(8)	(11)
Balance, $m
Balance, $m	Working capital	0	4	16	2	21	37	10	7	5	0
	Total debt	—	—	—	2	1	1	1	—	—	—
	Net debt	0	(5)	(16)	(6)	(18)	(35)	(17)	(4)	(8)	(5)
	Shareholders’ equity	0	12	39	36	36	54	31	13	10	5
Returns, %
Returns, %	ROA	(2.46)	(998.87)	(84.60)	(93.24)	(74.66)	(67.25)	(46.57)	(64.07)	(82.11)	(185.11)
	ROIC	0.00	0.00	(68.52)	(46.36)	(102.12)	(112.70)	(126.63)	(158.24)	(423.62)	(1,823.10)
	ROE	(2.76)	(54.91)	(67.67)	(103.45)	(87.62)	(78.03)	(55.76)	(82.40)	(121.65)	(336.82)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2018 · latest quarter Sep 2019

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BYSI BeyondSpring Inc.	$23.9M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
CYAD Celyad SA	$23.8M	— (loss-making)	— (loss-making)	—	n/m	+78.72% (above 0%: growing)	0.00%	0.00%	Compare
PLRZ Polyrizon Ltd.	$23.7M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
IMMP Prima BioMed Ltd	$23.7M	— (loss-making)	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)	Compare
EVAX Evaxion A/S - Sponsored ADR	$23.4M	— (loss-making)	— (loss-making)	+14,590.20% (above 0%: growing)	n/m	−56.70% (below 0%: shrinking)	100.00%	0.00%	Compare
ESLA Estrella Immunopharma, Inc.	$23.3M	— (loss-making)	—	—	n/m	−329.19% (below 0%: shrinking)	—	0.00%	Compare
CNTX Context Therapeutics Inc.	$22.1M	— (loss-making)	—	—	n/m	−20.61% (below 0%: shrinking)	0.00%	0.00%	Compare
QNTM Quantum Biopharma Ltd.	$21.9M	— (loss-making)	— (loss-making)	—	n/m	+5.88% (above 0%: growing)	0.00%	0.00%
KYNB Kyntra Bio Inc	$21.7M	0.1×	— (loss-making)	−209.35% (below 0%: shrinking)	n/m	−131.50% (below 0%: shrinking)	100.14%	1,192.27%	Compare
Median of peers	$23.5M	—	—	+87.78%	—	−94.10%	100.00%	0.00%

All 614 Biotechnology stocks →

Quantum Biopharma Ltd. (QNTM) key facts

Quantum Biopharma Ltd. (QNTM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, QNTM traded at $2.47, a market capitalization of $21.9 million.
Return on equity was −336.8% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.